Abattis Bioceuticals Corp. engages in the aggregation, integration, and investment in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The firm aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. The company operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. The company offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. The company is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.
최신 재무제표(Form-10K)에 따르면, Sumitomo Metal Mining Co Ltd의 총 자산은 $0이며, 순손실입니다.
ATTBF의 주요 재무 비율은 무엇인가요?
Sumitomo Metal Mining Co Ltd의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Abattis Bioceuticals Corp의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Sumitomo Metal Mining Co Ltd 주요 수익원은 Smelting이며, 최신 수익 발표에서 수익은 1,180,248,000,000입니다. 지역별로는 Japan이 Sumitomo Metal Mining Co Ltd의 주요 시장이며, 수익은 746,520,000,000입니다.
Abattis Bioceuticals Corp은 수익성이 있나요?
no, 최신 재무제표에 따르면 Sumitomo Metal Mining Co Ltd의 순손실은 $0입니다.